item management s discussion and analysis of financial condition and results of operations 
overview collagenex pharmaceuticals  inc began operations in january and is engaged in the development and commercialization of innovative  proprietary medical therapies for the treatment of periodontal disease and other pathologies 
since its origin  the company has had no revenues from sales of its own products and has funded its operations primarily from the proceeds of public and private issuances of equity securities 
substantially all of the company s expenditures to date have been for pharmaceutical development activities and general and administrative expenses 
since inception  the company has operated with a minimal number of employees 
substantially all pharmaceutical development activities  including clinical trials  have been contracted to independent contract research and other organizations 
the company anticipates that it will significantly increase the number of its employees over the next several years  primarily in the selling  general and administrative areas  following regulatory approval of periostat 
the company has incurred losses each year since inception and had an accumulated deficit of million at december  the company expects to continue to incur losses in the foreseeable future from expenditures on drug development  marketing  manufacturing and administrative activities 
statements contained or incorporated by reference in this annual report on form k that are not based on historical fact are forward looking statements within the meaning of section e of the securities exchange act of  as amended 
forward looking statements may be identified by the use of forward looking terminology such as may  will  expect  anticipate or similar terms  variations of such terms or the negative of those terms 
this form k contains forward looking statements that involve risks and uncertainties 
the company s business of developing pharmaceutical products is subject to a number of significant risks  including risks inherent in research and development activities and in conducting business in a highly regulated environment 
the success of the company depends to a large degree upon obtaining fda and foreign regulatory approval to market products currently under development 
there can be no assurance that any of the company s product candidates will be approved by any regulatory authority for marketing in any jurisdiction or  if approved  that any such products will be successfully commercialized by the company 
the company s actual results may differ materially from the results in the forward looking statements contained herein 
results of operations from its founding through december   the company had no revenues from sales of its own products 
operating expenses consist of research and development expenses and general and administrative expenses 
research and development expenses consist primarily of funds paid to contract research organizations for the provision of services and materials for drug development and clinical trials 
general and administrative expenses consist primarily of personnel salaries and benefits  professional and consulting fees  insurance  facilities and general office expenses 
the company anticipates that selling  general and administrative expenses will increase during the next several years due to the expansion of its commercial infrastructure  primarily in sales and marketing 
the company earned  in licensing fee revenue during compared to  during during  the company executed a licensing agreement with bmi pursuant to which bmi will  following regulatory approval  distribute and manufacture periostat in italy 
the agreement provided for bmi to pay a  license fee upon signing and additional fees upon the achievement of future milestones and royalties upon future sales of periostat in italy  san marino and the vatican city 
during the second quarter of  the company received a nonrefundable  licensing fee from bmi related to the achievement of the first milestone under the agreement 
years ended december  and december  research and development expenses decreased from million in to million in this decrease resulted primarily from lower costs associated with the nda for periostat  which was submitted in research and development expenses in related primarily to costs associated with completing a phase iii scaling and root planing trial  validating periostat manufacturing processes and continuing certain toxicology studies 
general and administrative expenses increased from million in to million in this increase was due primarily to higher marketing  general and administrative expenses associated with the expansion of the company s commercial infrastructure 
interest income increased from million to million in this increase was due to higher balances in cash and short term investments as a result of the company s follow on public offering of common stock in years ended december  and december  research and development expenses increased from million in to million in this increase resulted from higher contract costs associated with preparing and submitting a new drug application for periostat  including data compilation  statistical analysis and validation of production processes 
general and administrative expenses increased from million in to million in this increase was due primarily to higher employee compensation expense due to the hiring of additional staff in finance and commercial development  including a non cash compensation charge of approximately million resulting from the grant of certain employee stock options  and higher insurance and professional fees associated with becoming a public company 
interest income increased from million in to million in this increase was due to higher balances in cash and short term investments as a result of the company s initial public offering of common stock in liquidity and capital resources since its origin in january  the company has financed its operations through private placements of preferred stock and common stock  an initial public offering of  shares of common stock  which generated net proceeds to the company of approximately million after underwriting fees and related expenses  and a subsequent public offering of  shares of common stock  which generated net proceeds to the company of approximately million after underwriting fees and related expenses 
at december  the company s cash  cash equivalents and short term investments totaled million 
in accordance with investment guidelines approved by the company s board of directors  cash balances in excess of those required to fund operations have been invested in short term us treasury securities and commercial paper with a credit rating no lower than a p the company s working capital at december  was million  an increase of million from december  this increase was primarily attributable to the proceeds received from the company s follow on public offering of common stock in  which was reduced by normal operating expenses incurred during the company had no debt or capital leases outstanding other than accounts payable and accrued expenses at december  on june   the company entered into a credit arrangement consisting of a  line of credit the loc to support the future working capital needs of the company 
the loc will be unsecured as long as the company s cash and investment balances maintained with the lender or an affiliate of the lender equal or exceed million 
at the company s option  the loc will bear interest at either the prime rate charged by the lender or libor plus 
the loc is terminable by the lender at any time 
no balance was outstanding under the loc at december  the company anticipates that its existing working capital will be sufficient to fund the company s operations through at least the company s future capital requirements and the adequacy of its available funds will depend on many factors  including the timing of fda approval  if any  of the company s nda for periostat  such nda having been submitted to the fda in august  the size and scope of the company s sales and marketing effort  the terms of agreements entered into with corporate partners  if any  and the results of research and development and pre clinical and clinical studies for other applications of the company s core technology 
over the long term  the company s liquidity is dependent on market acceptance of its products and technology 
as of december   the company had available million and million in net operating carryforwards to offset future federal and state taxable income  if any  through the year and  respectively 
in addition  the company had research and experimentation tax credits of approximately  which expire at various times through the year as a result of past financings  including the company s initial public offering in june and the company s follow on public offering in april  the company experienced ownership changes as defined by rules enacted with the tax reform act of the reform act 
accordingly  the company s ability to use its net operating loss and research and experimentation credit carryforwards is subject to certain limitations as defined by the reform act and may be limited 

